230 related articles for article (PubMed ID: 25666253)
1. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?
Medarov BI; Judson MA
Respir Med; 2015 May; 109(5):557-64. PubMed ID: 25666253
[TBL] [Abstract][Full Text] [Related]
2. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
Sitbon O; Humbert M; Jaïs X; Ioos V; Hamid AM; Provencher S; Garcia G; Parent F; Hervé P; Simonneau G
Circulation; 2005 Jun; 111(23):3105-11. PubMed ID: 15939821
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.
Zuo XR; Zhang R; Jiang X; Li XL; Zong F; Xie WP; Wang H; Jing ZC
Am J Cardiol; 2012 Jun; 109(12):1801-6. PubMed ID: 22459309
[TBL] [Abstract][Full Text] [Related]
4. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G
Eur Respir J; 1998 Aug; 12(2):265-70. PubMed ID: 9727772
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
6. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.
Montani D; Savale L; Natali D; Jaïs X; Herve P; Garcia G; Humbert M; Simonneau G; Sitbon O
Eur Heart J; 2010 Aug; 31(15):1898-907. PubMed ID: 20543192
[TBL] [Abstract][Full Text] [Related]
7. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
Douwes JM; Humpl T; Bonnet D; Beghetti M; Ivy DD; Berger RM;
J Am Coll Cardiol; 2016 Mar; 67(11):1312-23. PubMed ID: 26988953
[TBL] [Abstract][Full Text] [Related]
8. Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension.
Saito Y; Nakamura K; Miyaji K; Akagi S; Mizoguchi H; Ogawa A; Fuke S; Fujio H; Kiyooka T; Nagase S; Kohno K; Morita H; Kusano KF; Matsubara H; Ohe T; Ito H
J Pharmacol Sci; 2012; 120(3):206-12. PubMed ID: 23117888
[TBL] [Abstract][Full Text] [Related]
9. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
Gerhardt F; Fiessler E; Olsson KM; Kayser MZ; Kovacs G; Gall H; Ghofrani HA; Badr Eslam R; Lang IM; Benjamin N; Grünig E; Halank M; Lange TJ; Ulrich S; Leuchte H; Held M; Klose H; Ewert R; Wilkens H; Pizarro C; Skowasch D; Wissmüller M; Hellmich M; Olschewski H; Hoeper MM; Rosenkranz S
Circulation; 2024 May; 149(20):1549-1564. PubMed ID: 38606558
[TBL] [Abstract][Full Text] [Related]
10. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment.
Hirakawa K; Asano R; Ueda J; Aoki T; Tsuji A; Ogo T
Int J Cardiol; 2024 Jul; 406():132043. PubMed ID: 38614366
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in children with idiopathic pulmonary arterial hypertension.
Yung D; Widlitz AC; Rosenzweig EB; Kerstein D; Maislin G; Barst RJ
Circulation; 2004 Aug; 110(6):660-5. PubMed ID: 15289375
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment: a case report.
Hirakawa K; Aoki T; Tsuji A; Ogo T
Eur Heart J Case Rep; 2022 Sep; 6(9):ytac351. PubMed ID: 36072422
[TBL] [Abstract][Full Text] [Related]
14. The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension.
Solik P; Lesny P; Luknar M; Varga I; Goncalvesova E
Bratisl Lek Listy; 2013; 114(5):283-6. PubMed ID: 23611052
[TBL] [Abstract][Full Text] [Related]
15. Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing.
Chandrasekara S; Lau EM; Anderson J; Collins N; Cordina R; Corrigan C; Dwyer N; Feenstra J; Horrigan M; Keogh A; Kotlyar E; Lavender M; McWilliams T; Rhodes B; Steele P; Strange G; Thakkar V; Weintraub R; Whitford H; Whyte K; Williams T; Wrobel J; Keating DT;
Heart Lung Circ; 2023 Feb; 32(2):156-165. PubMed ID: 36503731
[TBL] [Abstract][Full Text] [Related]
16. Updated treatment algorithm of pulmonary arterial hypertension.
Galiè N; Corris PA; Frost A; Girgis RE; Granton J; Jing ZC; Klepetko W; McGoon MD; McLaughlin VV; Preston IR; Rubin LJ; Sandoval J; Seeger W; Keogh A
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D60-72. PubMed ID: 24355643
[TBL] [Abstract][Full Text] [Related]
17. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension.
Jing ZC; Jiang X; Han ZY; Xu XQ; Wang Y; Wu Y; Lv H; Ma CR; Yang YJ; Pu JL
Eur Respir J; 2009 Jun; 33(6):1354-60. PubMed ID: 19213781
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Vascular Capacitance is Associated with Vasoreactivity and Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension.
Cheng XL; He JG; Liu ZH; Gu Q; Ni XH; Zhao ZH; Luo Q; Xiong CM
Lung; 2016 Aug; 194(4):613-8. PubMed ID: 27272652
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
20. Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.
Chakinala MM
Semin Respir Crit Care Med; 2005 Aug; 26(4):409-16. PubMed ID: 16121318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
